Peptic ulcer sickness, gastroesophageal reflux-disease as well as Helicobacter pylori diseases are key health issues that require effective gastric reducing therapy. This paper reviews the safety and efficacy of vonoprazan used in comparison with standard proton pump inhibitors (PPIs). Clinical trials show that vonoprazan is a more effective acid reducer compared to other drugs and does not rely on the level of stomach acid, as it works by blocking the H+, K+-ATPase pump. It demonstrates superior H. pylori eradication rates (87.997.4 vs. 57.382.0 percent with PPIs) and healing of erosive esophagitis, and peptic ulcers (>92 percent). Short-term safety profile is similar to PPIs, however, skin disorders, liver, and hemorrhagic entero-colitis are more common issues. Long-term safety has not been established, and this will need monitoring. Vonoprazan is rapid (2 h to 4 h), long-lasting (24 h), genetic and diet-independent. Long-term use should be further studied.